Private Equity

With promising data in hard-to-treat cancers, iOnctura's lead drug, roginolisib, is set to make waves at the top healthcare investment forum.

The brokerage closed deals with 150 lenders in 2025, adding 48 new partners. How did this strategy help them navigate a complex real estate landscape?

With a massive $200M Series A and a promising Phase 2 drug, new biotech AirNexis aims to reshape the multi-billion dollar COPD treatment landscape.

Global investment giant Lone Star Funds acquires a second major office asset in South Florida, signaling strong confidence in the region's booming market.

Koppers Holdings navigates a key leadership change as CFO Jimmi Sue Smith retires. Veteran Bradley Pearce takes the helm as interim financial chief.

With a huge new investment, MEDIPOST is advancing its proven stem cell therapy for knee osteoarthritis into a pivotal Phase III trial in the United States.

Aesthetics firm Evolus reports its first profitable quarter and robust growth, banking on new products and international markets to defy industry slowdowns.

With a key drug in late-stage trials and a bolstered team, Palvella Therapeutics aims to deliver the first FDA-approved therapies for rare skin diseases.

Private equity giant Bain Capital and BlueWater Marinas acquire Kent Narrows Boatel, signaling a new wave of investment in the luxury boating market.

With up to $80.8M in new funding, Curis is set to accelerate trials for emavusertib, a promising drug targeting some of the toughest blood cancers.

A perfect storm of economic shifts and private equity pressure is set to ignite the dental M&A market, creating huge opportunities for practice owners.

Indonesia Energy Corp. starts pre-drilling for two new wells in Sumatra, a key move in its growth strategy and a boost for national energy security.

Radiant Ridge Energy's new 40MW project in Alberta bypasses the grid, converting natural gas directly into power for the booming AI and data industry.

Swiss lab automation giant Tecan shows signs of a turnaround with robust H2 2025 orders, betting on AI to navigate a recovering life sciences market.

As Valneva meets investors, all eyes are on its pivotal Lyme disease vaccine data, a potential game-changer for public health and the company's future.

A new report reveals shifting consumer demands for THCA flower, as the booming market grapples with quality standards and a complex regulatory future.

Ventyx Biosciences is under investigation for misleading investors after a trial delay caused a 15% stock drop, even as a pharma giant moves to acquire it.

Boston's Moody Aldrich Partners commits $600M to London's SCIO Capital, a major validation of specialized asset-backed lending in Europe's booming market.

A legal battle over the blockbuster cancer drug Jemperli escalates, with billions in future royalties and a company's strategic future on the line.

With a 12% increase in gold reserves, Aris Mining's Segovia mine proves its mettle as a world-class asset, fueling an aggressive expansion in South America.